Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

HMGB1 accelerates regeneration of multiple tissues by transitioning stem cells to G(Alert)

Lee G. et al, (2018), AUSTRALASIAN JOURNAL OF DERMATOLOGY, 59, 83 - 83

Method of treating a localized fibrotic disorder using an IL-33 antagonist

NANCHAHAL J. et al, (2018)

What do we know about managing Dupuytren's disease cost-effectively?

Dritsaki M. et al, (2018), BMC Musculoskelet Disord, 19

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD).

Png ME. et al, (2018), Wellcome open research, 3

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD).

Png ME. et al, (2018), Wellcome Open Res, 3

HMGB1 Accelerates Regeneration of Multiple Tissues By Transitioning Stem Cells to G(Alert)

Lee G. et al, (2017), BLOOD, 130

HMGB1 accelerates regeneration of multiple tissues by transitioning stem cells to G(Alert)

Lee G. et al, (2017), JOURNAL OF BONE AND MINERAL RESEARCH, 32, S48 - S48

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.

Nanchahal J. et al, (2017)

A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.

Ng M. et al, (2017), Am J Hum Genet, 101, 417 - 427

Does negative-pressure wound therapy influence subjacent bacterial growth? A systematic review.

Glass GE. et al, (2017), J Plast Reconstr Aesthet Surg, 70, 1028 - 1037

Open tibial fractures

Fernandez MA. et al, (2017), Orthopaedics and Trauma, 31, 125 - 132

Anti-TNF Therapy

Udalova I. et al, (2017), Myeloid Cells in Health and Disease: A Synthesis, 637 - 648

Anti-TNF Therapy

Udalova I. et al, (2017), MYELOID CELLS IN HEALTH AND DISEASE, 637 - 648

Gastrocnemius Muscle Flaps for Lower Limb Reconstruction

Atherton D. et al, (2017), FLAPS: PRACTICAL RECONSTRUCTIVE SURGERY, 224 - 229

Recurrence of Dupuytren's contracture: A consensus-based definition.

Kan HJ. et al, (2017), PLoS One, 12

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.

Nanchahal J. et al, (2017), Wellcome Open Res, 2

Tonometry as an outcome measure for early Dupuytren's disease

BALL C. et al, (2016), Dupuytren Disease and Related Diseases - The Cutting Edge

Systematic review of non-surgical treatments for early dupuytren’s disease

Ball CE. et al, (2016), Biomedcentral Musculoskeletal Disorders

Systematic review of non-surgical treatments for early dupuytren's disease.

Ball C. et al, (2016), BMC Musculoskelet Disord, 17

Anti-TNF Therapy.

Udalova I. et al, (2016), Microbiol Spectr, 4

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?